ABSTRACT
IMPORTANCE Asymptomatic SARS-CoV-2 infections are potential sources for transmission; characterization of these cases has not been conducted in most low/middle income countries, including Mexico.
OBJECTIVES To profile pre-symptomatic/asymptomatic SARS-CoV-2 infections in Mexico City, its associated comorbidities and outcomes.
DESIGN Prospective observational study
SETTING Subjects assessed by convenience sampling within the National Epidemiological Surveillance System in Mexico City.
PARTICIPANTS Subjects with and without respiratory and non-respiratory symptoms (RS, NRS, respectively) assessed for SARS-CoV-2 using real time RT-PCR from nasopharyngeal swabs.
OUTCOMES Severe COVID-19, intensive care unit admission, 30-day mortality and their outcomes in cases RS or NRS and asymptomatic cases.
RESULTS Amongst 60121 cases with confirmed SARS-CoV-2 infection as of July 1st, 2020, we identified 5982 cases without RS (9.9%) and 2452 who were asymptomatic at first evaluation (4.1%). Compared to cases with RS, NRS and asymptomatic cases were younger and had lower rates of comorbidities. Cases with NRS had higher rates of severe COVID-19 outcomes including hospitalization, ICU admission, and intubation (p<0.001). Mortality was higher for cases with NRS (HR 3.13, 95%CI 1.80-5.45) or RS (HR 7.58, 95%CI 4.56-12.58) compared to asymptomatic cases, adjusted for age, sex and comorbidities. Predictors for mortality in cases without RS included older age, previous exposure to suspected viral infection cases, comorbidities, presence of NRS and vomiting. For asymptomatic SARS-Co-V-2 infections, chronic kidney disease, previous exposure with suspected infection cases and older age were predictors for lethality.
CONCLUSIONS AND RELEVANCE Definition of pre-symptomatic/asymptomatic cases has relevant implications for SARS-CoV-2 infection outcomes. Older age and comorbidity impact on the probability of developing severe complications for cases who were asymptomatic or had only NRS at evaluation and were sent for domiciliary treatment. Extending testing for detection of asymptomatic cases must be considered in Mexico to better understand the impact of the pandemic.
Question What are the profiles and outcomes of pre-symptomatic/asymptomatic cases of SARS-CoV-2 infection in Mexico City?
Findings In this prospective observational study, we identified that cases with SARS-CoV-2 infection who were asymptomatic/pre-symptomatic at initial evaluation were younger with low rates of comorbidities, had higher rates of previous viral exposure or were healthcare workers. Compared to asymptomatic cases at first evaluation, cases with non-respiratory symptoms had higher risk of severe COVID-19 outcomes. Predictors for mortality in non-respiratory or asymptomatic cases included non-respiratory symptoms, comorbidity and older age.
Meaning Definition of pre-symptomatic/asymptomatic cases has relevant implications for outcomes related to SARS-CoV-2 infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No approval was required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTERESTS: Nothing to disclose.
FUNDING: This research received no specific funding
Data Availability
All data sources and R code are available for reproducibility of results at https://github.com/oyaxbell/covid_asymptomatic_cdmx.
